Invitrogen™ PD-L1 Recombinant Human Monoclonal Antibody (332M7)

Description

This antibody strongly binds human and cynomolgus monkey PD-L1 and shows weak binding for mouse PD-L1. PD-L1 is highly expressed in many human tumors. . PD-L1 exerts an immune suppressive signal through binding to PD-1 and B7.1, and tumor expression of PD-L1 can mediate cancer immune evasion. Blocking this pathway, therefore provides a rationale for cancer immunotherapy.

Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation. Thus, PD-L1 might play an important role in tumor immune evasion.